Chiesi Farmaceutici S.p.A.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Chiesi Farmaceutici S.p.A. sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).
Chiesi Farmaceutici S.p.A.: 30 sponsored US clinical trials, 4 recruiting.
Chiesi Farmaceutici S.p.A. sponsors 30 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 18 completed. 9 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fabry Disease, with 4 trials.
Top-decile sponsor footprint
Chiesi Farmaceutici S.p.A. ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
30 total, page 1 of 1
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
NCT06941025
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
NCT06184503
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
NCT06663358
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
NCT03614234
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
NCT05830071
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
NCT05292586
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
NCT05186324
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
NCT04636801
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration
NCT02772081
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
NCT04502433
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
NCT04104646
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
NCT03594175
Registry Study of Revcovi Treatment in Patients With ADA-SCID
NCT03878069
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
NCT03566017
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
NCT03086460
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
NCT03084796
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
NCT03084718
Cangrelor Neonatal PK/PD and Safety Study
NCT02765633
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
NCT02452476
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)
NCT02123667
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
NCT01938547
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
NCT01602393
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
NCT01421056
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00782535
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
NCT00777595
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
NCT00640484
Dose Finding Study of CHF 4226 for Treating Patients With COPD
NCT00605891
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Chiesi Farmaceutici S.p.A. pipeline
4 recruiting of 30 indexed (13% open); 18 completed (60%).
Phase mix: 9 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Fabry Disease (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Chiesi Farmaceutici S.p.A.: open-pipeline peers nationwide
Peers matched on 30 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Chiesi Farmaceutici S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 30 trials (± recruiting share)
- Biotronik · 30 trials · 3% recruiting
- Charles Drew University of Medicine and Science · 30 trials · 3% recruiting
- Debiopharm International · 30 trials · 17% recruiting
- Exact Sciences Corporation · 30 trials · 10% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
- European Organisation for Research and Treatment of Cancer - EORTC · 13% recruiting · 15 trials
Related
What to do with this Chiesi Farmaceutici S.p.A. page
30 registered trials is a research-attention snapshot, not an endorsement of Chiesi Farmaceutici S.p.A. or any single study.
- 4 of Chiesi Farmaceutici S.p.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Fabry Disease is the condition Chiesi Farmaceutici S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fabry Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Chiesi Farmaceutici S.p.A. pipeline card: 30 registered trials from official public datasets.Report a data error.